MDXG - Activist investor discloses stake in MiMedx and suggests company to consider strategic alternatives

The activist investor, Prescience Point has revealed ~8% stake in MiMedx Group ([[MDXG]] +0.8%) as indicated by regulatory filing, which represents over 8.7M shares.The investor also says that after completing Phase 2b Knee OA trial evaluating dHACM injection, the company should consider alternatives including a sale of the company or of its Amniofix product to a strategic buyer as the value of the pipeline of clinical trials for Amniofix “far exceeds” that of the company’s advanced wound care business.Results from 82 subjects with 100 treated knees, showed dHACM to be a potentially useful treatment option for patients with knee OA.Osteoarthritis score for the cohort was 40 at baseline, improving to 52, 62 and 65 at 6 weeks, 3 months and 6 months post-dHACM injection.By 6 weeks, the assessment in the Osteoarthritis score sub-scale for dHACM injection showed mean score by greater than 10 points. By 6 months, differences of 24.8-30 points were observed in all sub-categories.There

For further details see:

Activist investor discloses stake in MiMedx and suggests company to consider strategic alternatives